Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients
Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients have?
Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients has 251 citations in the OpenAlex counts ScholarIQ stores.
When was Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients published?
Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients has 2017 year in the ScholarIQ index.
What is the open-access status of Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients?
Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients has gold oa status in the ScholarIQ index.
What is the DOI of Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients?
The DOI for Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients is on the source record.
What is the PMID of Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients?
The PMID for Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients is on the source record.
What is the OpenAlex record for Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients?
The OpenAlex for Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients is on the source record.